Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at William Blair issued their Q1 2018 earnings per share (EPS) estimates for shares of Gilead Sciences in a report issued on Thursday. William Blair analyst Y. Xu expects that the biopharmaceutical company will earn $1.78 per share for the quarter. William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Gilead Sciences’ Q2 2018 earnings at $1.76 EPS, Q3 2018 earnings at $1.74 EPS and Q4 2018 earnings at $1.74 EPS.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.08 EPS.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/gilead-sciences-inc-to-post-q1-2018-earnings-of-1-78-per-share-william-blair-forecasts-gild.html.

A number of other equities research analysts have also issued reports on GILD. BMO Capital Markets reissued a “hold” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Friday. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday. Leerink Swann lifted their target price on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research report on Thursday. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $85.64.

Gilead Sciences (GILD) opened at 81.21 on Monday. The company has a 50-day moving average price of $82.63 and a 200-day moving average price of $72.65. The firm has a market cap of $106.05 billion, a P/E ratio of 8.82 and a beta of 1.14. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In other news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock valued at $36,338,919 over the last three months. Company insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. APG Asset Management N.V. grew its position in shares of Gilead Sciences by 4.0% in the third quarter. APG Asset Management N.V. now owns 5,754,214 shares of the biopharmaceutical company’s stock valued at $466,206,000 after purchasing an additional 222,200 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co grew its position in shares of Gilead Sciences by 1.5% in the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 69,658 shares of the biopharmaceutical company’s stock valued at $5,644,000 after purchasing an additional 1,048 shares in the last quarter. Douglas Lane & Associates LLC grew its position in shares of Gilead Sciences by 17.1% in the third quarter. Douglas Lane & Associates LLC now owns 11,725 shares of the biopharmaceutical company’s stock valued at $950,000 after purchasing an additional 1,715 shares in the last quarter. Oakbrook Investments LLC grew its position in shares of Gilead Sciences by 1.0% in the third quarter. Oakbrook Investments LLC now owns 384,094 shares of the biopharmaceutical company’s stock valued at $31,119,000 after purchasing an additional 3,621 shares in the last quarter. Finally, OLD Second National Bank of Aurora grew its position in shares of Gilead Sciences by 55.5% in the third quarter. OLD Second National Bank of Aurora now owns 2,942 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 1,050 shares in the last quarter. Institutional investors own 73.97% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.